Tag Archives: decompensated heart failure

Introduction Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, was first used as a type 2 diabetes drug. However, in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial, dapagliflozin effectively reduced both hospitalisations due to heart failure (HF) and death in patients with HF with reduced ejection fraction (HFrEF).1 Therefore, the European Society of Cardiology (ESC) and Japanese Circulation Society (JCS) guidelines recommended the administration of SGLT2 inhibitors to patients with HFrEF.2,3 Moreover, dapagliflozin suppressed both renal failure exacerbation and all-cause death in patie

Multipolar left ventricular pacing to optimise acute haemodynamic response to cardiac resynchronisation therapy SY Ahsan (presenting author), B Sabberwal, C Hayward, P Lambiase, M Thomas, GG Babu, S Aggarwal, MD Lowe, AWC Chow The Heart Hospital, Institute of Cardiovascular Science, University College Hospitals NHS Foundation Trust, London Purpose: Cardiac resynchronisation therapy (CRT) reduces morbidity and mortality in a sub-group of patients with heart failure, though up to 30% of patients have no benefit. CRT patients are heterogeneous and an individualised approach to CRT may be needed to increase response rate. We evaluated the impact

No content available